http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01469.x/pdf
At week 96, five patients of Group 1 plus Group 2
reporting HBsAg loss reached 21.7% (5/23) by two-step
Pegasys treatment, and three more patients had low titre of
HBsAg (<5 IU/mL) and low HBV DNA levels (<1000 copies/
mL) with ALT normalization.
Efficacy of two-step Pegasys treatment in HBeAg-positive
vs HBeAg-negative CHB
For comparison of the efficacy of two-step Pegasys treatment
between Group 1 (HBeAg positive) and Group 2 (HBeAg
negative), the rates of HBsAg clearance and seroconversion
at week 96 were 15.4% (2/13) and 7.7% (1/13) for HBeAgpositive patients; 30% (3/10) and 20% (2/10) for HBeAgnegative patients. The rates of undetectable HBV DNA were
30.8% (4/13) and 30% (3/10, P = 0.968); SVR were 69.2%
(9/13) and 80% (8/10, P = 0.56) for HBeAg-positive and
HBeAg-negative patients, respectively, at week 96. No significant difference was observed (Fig. S1)